+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Armagen - logo

ArmaGen is a privately held, clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Currently, ArmaGen has eight compounds in development. The company’s lead product candidates are AGT-182 for Hunter syndrome, which is in Phase 1 clinical trials, and AGT-181 for Hurler syndrome, which is in Phase 2 trials. ArmaGen’s headquarters and research operations are located in Calabasas, CA.

Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions - Product Thumbnail Image

Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions

  • Report
  • September 2024
  • 375 Pages
  • Global
From
Drug Delivery Across Blood Brain Barriers - Global Strategic Business Report - Product Thumbnail Image

Drug Delivery Across Blood Brain Barriers - Global Strategic Business Report

  • Report
  • January 2026
  • 297 Pages
  • Global
From
Duchenne Muscular Dystrophy Market Report 2025 - Product Thumbnail Image

Duchenne Muscular Dystrophy Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Central Nervous System Collaboration and Licensing Deals 2019-2025 - Product Thumbnail Image

Central Nervous System Collaboration and Licensing Deals 2019-2025

  • Report
  • October 2025
  • 500 Pages
  • Global
From
Hunter Syndrome Treatment - Global Strategic Business Report - Product Thumbnail Image

Hunter Syndrome Treatment - Global Strategic Business Report

  • Report
  • January 2026
  • 280 Pages
  • Global
From
Metachromatic Leukodystrophy Treatment Market - Global Strategic Business Report - Product Thumbnail Image

Metachromatic Leukodystrophy Treatment Market - Global Strategic Business Report

  • Report
  • January 2026
  • 283 Pages
  • Global
From
Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 40 Pages
  • Global
From
Lysosomal Storage Diseases Market - Global Forecast 2026-2032 - Product Thumbnail Image

Lysosomal Storage Diseases Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 192 Pages
  • Global
From
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • September 2022
  • 672 Pages
  • Global
From
Hunter Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Hunter Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Metachromatic Leukodystrophy (MLD) - Pipeline Insight, 2025 - Product Thumbnail Image

Metachromatic Leukodystrophy (MLD) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Hunter Syndrome Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028) - Product Thumbnail Image

Hunter Syndrome Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

  • Report
  • April 2023
  • 110 Pages
  • Global
From
Metachromatic Leukodystrophy Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Metachromatic Leukodystrophy Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • October 2024
  • 77 Pages
  • Global
From
Rett Syndrome Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Rett Syndrome Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • September 2024
  • 89 Pages
  • Global
From
Mucopolysaccharidosis II Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Thumbnail Image

Mucopolysaccharidosis II Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • February 2024
  • 94 Pages
  • Global
From
Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights - Product Thumbnail Image

Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

  • Report
  • May 2018
  • 204 Pages
  • Global
From
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 73 Pages
  • Global
From
Wearable Injectors Market Industry Trends and Global Forecasts to 2035, by Type of Device, Usability, Therapeutic Area and Key Geographical Regions - Product Thumbnail Image

Wearable Injectors Market Industry Trends and Global Forecasts to 2035, by Type of Device, Usability, Therapeutic Area and Key Geographical Regions

  • Report
  • January 2025
  • 690 Pages
  • Global
From
Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 49 Pages
  • Global
From
Stroke - Pipeline Review, H2 2020 - Product Thumbnail Image

Stroke - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 773 Pages
  • Global
From
  • 20 Results (Page 1 of 1)
Loading Indicator